



Building trust with society: our priorities

Pricing and access to medicines

Being part of the solution and broadening our scope and impact

16 m

PATIENTS

reached through our access programs

4.5 m

MONTHLY TREATMENTS

delivered through Novartis Access
to 12 countries since 2015

10 m+

PEOPLE

reached through training and
health education

300 000+

PATIENTS

reached with over 90 local brands for some
of our most advanced medicines

Global health challenges

Helping tackle neglected diseases such as malaria, leprosy, Chagas disease and sickle cell disease

900 m+

ANTIMALARIAL TREATMENT COURSES

delivered since 2001, including more
than 390 m treatments for children

Initiated the development of a new
formulation of our antimalarial *Coartem*
for infants weighing less than 5 kilograms

900

CHAGAS PATIENTS

to be recruited for a first-of-its-kind clinical trial
in patients with Chagas-related heart failure

7 m+

LEPROSY PATIENTS

7 m+ patients reached worldwide with
free multidrug therapy since 2000

20 000+

HYDROXYUREA TREATMENTS

delivered to Ghana for the treatment of patients
with sickle cell disease

Ethical standards

Holding ourselves to the highest ethical standards to maintain the respect and trust of society

500+

ASSOCIATES

volunteered to be part of the network that will create the Novartis Code of Ethics

135

HIGH LEVEL AUDITS

performed on 100% of suppliers with active follow-up

5-year

HUMAN RIGHTS STRATEGY

introduced, while integrating the function with Third-Party Risk Management

99/100

SCORE

achieved by Novartis for clinical trial transparency in a recent analysis published by BMJ

Corporate responsibility

Making a positive contribution to society and expanding our social impact

102 bn

CONTRIBUTED (USD, 2018)

to the global gross domestic product and 1.3 m jobs provided beyond those held by our own employees through Novartis activities

80 000

TONNES REDUCTION

of carbon emissions (Scope 1 and 2) vs. 2016, with an aim to be carbon neutral by 2025

67 bn

SOCIAL IMPACT (USD, 2018)

of a large part of our Innovative Medicines portfolio in 117 countries, based on the estimated value of health benefits to patients

44%

WOMEN

in management, with a goal of achieving gender balance by 2023